gp145 c.6980 vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 27, 2017 (NCT03382418)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04826094 | Phase 1 | Mar 16, 2021 | Kenya Medical Research Institute, National Institute of Allergy and Infectious Diseases (NIAID), The EMMES Corporation, United States Army |
| NCT03382418 | Phase 1 | Dec 27, 2017 | National Institute of Allergy and Infectious Diseases (NIAID), New York Blood Center, University of Pennsylvania |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2017 |
| Kenya Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| New York Blood Center | Academic/Hospital | 1 | 0 | 1 | 2017 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2021 |
| United States Army | Government | 1 | 0 | 1 | 2021 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1